SQZ Biotechnologies EBITDA 2020-2022 | SQZ
SQZ Biotechnologies ebitda from 2020 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
SQZ Biotechnologies Annual EBITDA
(Millions of US $) |
| 2022 |
$-69 |
| 2021 |
$-58 |
| 2020 |
$-40 |
| 2019 |
$-31 |
SQZ Biotechnologies Quarterly EBITDA
(Millions of US $) |
| 2022-12-31 |
$-11 |
| 2022-09-30 |
$-20 |
| 2022-06-30 |
$-20 |
| 2022-03-31 |
$-18 |
| 2021-12-31 |
$-9 |
| 2021-09-30 |
$-20 |
| 2021-06-30 |
$-16 |
| 2021-03-31 |
$-13 |
| 2020-12-31 |
$-15 |
| 2020-09-30 |
$-10 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-8 |
| 2019-12-31 |
|
| 2019-09-30 |
$-8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.018B |
$0.021B |
|
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
|
